Characterizing and correcting immune dysfunction in non-tuberculous mycobacterial disease.

Area of Science:

• Immunology
• Pulmonology
• Microbiology

Background:

• Non-tuberculous mycobacterial pulmonary disease (NTM-PD) is a growing global health concern requiring better management strategies.
• Understanding the immune system's role in NTM-PD is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the temporal immune responses during pulmonary infections caused by Mycobacterium avium complex (MAC) and Mycobactereoides abscessus complex (MABS).
• To identify immune biosignatures that correlate with disease stage and infecting species.
• To explore the therapeutic potential of targeting immune checkpoints in NTM-PD.

Main Methods:

• Analysis of immune cell populations and their activation markers (TIM-3, CTLA-4) in patients with NTM-PD.
• Comparison of immune profiles between active infection, treatment failure, and healthy individuals.
• Assessment of the impact of programmed cell death protein 1 (PD-1) blockade on T cell function.

Main Results:

• Active MAC infection showed increased T cell immunoglobulin and mucin-domain containing-3 (TIM-3) expression, while active MABS infection showed increased cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) expression.
• Patients with treatment failure exhibited immune profiles similar to healthy individuals, suggesting immune evasion.
• Identified accurate immune biosignatures for disease staging and species identification.
• PD-1 blockade restored antigen-specific IFN-γ secretion in most disease stages, except in persistent infections.

Conclusions:

• Distinct immune responses characterize MAC and MABS pulmonary infections, offering species-specific insights.
• Immune biosignatures can aid in diagnosing and staging NTM-PD.
• Checkpoint inhibitors, like PD-1 blockade, show potential for treating NTM-PD, though efficacy may vary in persistent infections.